Bovine AGE-BSA Biotinylated Protein, CF

Catalog # Availability Size / Price Qty
Product Details
Citations (1)
Supplemental Products

Bovine AGE-BSA Biotinylated Protein, CF Summary

Product Specifications

Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Measured by its ability to bind immobilized rmLOX-1 (Catalog # 1564-LX) in an ELISA type binding assay with an estimated KD <75 nM.
Bovine serum-derived AGE-BSA protein
Advanced glycation end product (AGE) of bovine serum albumin (AGE-BSA) was prepared by incubating BSA and glucose under sterile conditions at 37 °C for 60 days and then biotinylated.

Product Datasheets

You must select a language.



Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.


Formulation Lyophilized from a 0.2 μm filtered solution in PBS.

Reconstitute at 1 mg/mL in sterile PBS.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Background: AGE-BSA

Advanced glycation end products (AGEs) are formed by the non-enzymatic reaction of reducing sugars with amino groups on macromolecules (1, 2). Glycation is accomplished by the Maillard reaction, which is a multistep process that begins with Schiff base formation between the amine and the carbonyl group on the sugar followed by rearrangement to form Amadori intermediates. The intermediates are oxidized to highly reactive dicarbonyl compounds which target the primary amino groups in lysine and arginine residues (3). Some AGEs involve protein crosslinking, while others, such as N epsilon -carboxymethyl lysine (CML), are confined to single molecules (3). The final step of AGE formation is essentially irreversible, but the Schiff bases and Amadori intermediates are susceptible to degradation (4, 5). The Maillard reaction is accelerated under hyperglycemic and oxidative conditions. Renal failure, dietary AGE intake, and the normal aging process also contribute to the in vivo accumulation of AGEs (6 - 8). Increased AGE accumulation may be both a cause and effect of diabetes as well as multiple chronic inflammatory conditions such as Alzheimer’s disease, atherosclerosis, and arthritis (1, 2). AGEs can bind a variety of receptors, including RAGE, AGE-R1, -R2, -R3, and the scavenger receptors CD36, LOX-1, SR-AI, SR-AII, SR-BI, Stabilin-1/FEEL-1, and Stabilin-2/FEEL-2 (1). RAGE is a multiligand receptor that is upregulated on macrophages, monocytes, smooth muscle cells, and endothelial cells in response to AGE accumulation (9). RAGE activation induces a broad proinflammatory response (1, 2, 10). The increased production of reactive oxygen species promotes additional AGE formation and RAGE upregulation, a cycle that exacerbates diabetic complications and inflammation-induced tissue injury (1, 2).

  1. Goldin, A. et al. (2006) Circulation 114:597.
  2. Ramasamy, R. et al. (2005) Glycobiology 15:16R.
  3. Reddy, V.P. and A. Beyaz (2006) Drug Discov. Today 11:646.
  4. Szwergold, B.S. et al. (2001) Diabetes 50:2139.
  5. Szwergold, B.S. et al. (2005) Ann. N.Y. Acad. Sci. 1043:845.
  6. Thornalley, P.J. (2006) J. Ren. Nutr. 16:178.
  7. Chuyen, N. et al. (2006) Mol. Nutr. Food Res. 50:1140.
  8. Yin, D. and K. Chen (2005) Exp. Gerontol. 40:455.
  9. Bierhaus, A, et al. (2006) Curr. Opin. Investig. Drugs 7:985.
  10. Kislinger, T. et al. (1999) J. Biol. Chem. 274:31740.
Long Name
Advanced Glycation Endproducts of Bovine Serum Albumin
Alternate Names

Citation for Bovine AGE-BSA Biotinylated Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

1 Citation: Showing 1 - 1

  1. Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation.
    Authors: Li S, Huang P, Yang A, Tarng D, Yang W, Lin C, Chen J, Schmid-Schonbein G, Lin S
    Kidney Int, 2014;86(2):358-69.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay


No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Bovine AGE-BSA Biotinylated Protein, CF

There are currently no reviews for this product. Be the first to review Bovine AGE-BSA Biotinylated Protein, CF and earn rewards!

Have you used Bovine AGE-BSA Biotinylated Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review